Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced the launch and full commercial availability of the UG 100™ at the upcoming Advances in Genome Biology and Technology (AGBT) conference on February 5, 2024.

The UG 100™ system, Ultima’s first commercial product, leverages a unique sequencing architecture featuring an open silicon wafer to replace multiple traditional flow cells and enable the $100 genome and beyond. The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications. The system features full 24/7 run automation, flexibility for smaller and significantly faster runs, high accuracy for germline applications and an extreme accuracy mode for somatic applications and rare event detection.

“After much anticipation, we are excited to publicly announce the full commercial availability of the $100 genome at the upcoming AGBT conference in February,” said Gilad Almogy, Founder and CEO of Ultima. “When we designed our new sequencing technology, we took on the considerable challenge of creating an entirely new architecture that addressed key shortcomings faced by sequencers today. Not only does our platform enable the $100 genome and a roadmap beyond, but it also enables extreme accuracy and features our proprietary ppmSeq™ technology for applications where it is needed most. Given the significant departure from the status quo, we wanted to work in partnership with our large customers through an early access program to mature the technology and prove its advantages in large applications. We would like to thank our early access partners for their collective efforts in helping us to make the UG 100™ and the Era of the $100 genome and beyond a reality.”

Since exiting stealth mode and unveiling the $100 genome at AGBT in 2022, Ultima has been continually improving its system through a robust Early Access program. Ultima has partnered with many leading laboratories spanning large genome centers and core labs, centralized CLIA labs, biotech companies and academic centers to mature the technology.

The UG 100™ platform incorporates several significant hardware upgrades to improve instrument robustness and usability, automation capabilities to provide 24/7 run automation for productivity, coupled with enhanced chemistry and analytics for faster run times and improved accuracy. This commercial version of Ultima’s sequencing platform will also include a new ppmSeq™ technology that provides industry-leading raw read accuracy for calling single nucleotide variants (SNVs) for rare event detection applications like detecting low-level circulating tumor DNA.

“We have seen the evolution and maturation of the UG 100™ from its early stages up to commercial launch and have been impressed by the improvements in accuracy, reliability, and productivity,” said Stacey Gabriel, Executive Vice President of Platforms and Scientific Execution at Broad Institute of MIT and Harvard. “The system’s attributes will be applicable to large-scale programs in our production environment, and we are now deploying the commercial UG 100™ in our commercial operations.”

“Genomic information at scale enables more efficient drug discovery and development,” said John Overton, PhD, Vice President and Chief Sequencing Officer, Regeneron Genetics Center®. “The Ultima technology has the potential to take a giant step forward to overcome cost obstacles. We were one of the first early access customers to work with the UG 100™ and we look forward to working with the Company to advance its technology even further in the future.”

“We are excited by the unique approach that Ultima took with its technology and the work their team has done to advance the technology for launch,” said Dan Landau of The New York Genome Center. “Due to its significant departure from legacy approaches, Ultima’s technology has unique advantages that overcome challenges of traditional sequencing approaches. Ultima’s ppmSeq™ technology, for example, can be transformative for a variety of somatic applications requiring extreme SNV accuracy, such as cell-free DNA and liquid biopsy. We are deploying Ultima’s technology towards a variety of applications spanning cell-free DNA, liquid biopsies, whole genome sequencing and other omics and counting applications.”

“At Exact Sciences, our mission is to help eradicate cancer through tests that prevent it, detect it earlier and guide treatment,” said Jorge Garces, Chief Science Officer at Exact Sciences. “Access to accurate and affordable genomic technologies is critical for us to provide patients and healthcare providers with reliable test information before diagnosis and across all stages of cancer treatment. We have been impressed with Ultima’s approach to partnership with its customers and are excited to further explore the potential to employ their technology in our research and product development efforts.”

“Ultima’s new high throughput technology is unique and addresses specific challenges with conventional high throughput technologies. We are excited to be an early adopter of Ultima’s technology and the first to have the instrument installed in the Asia-Pacific region. The platform’s advantages of cost, flexibility and accuracy for applications where it is needed most is a significant benefit,” said Changhoon Kim, CEO of Macrogen. “We look forward to bringing this benefit to customers globally.”

"We are entering an exciting time in biology and medicine, where AI and low-cost sequencing will enable population-level studies, improved diagnosis of disease, and planetary-scale experiments that were impossible only a few years ago," said Dr. Chris Mason, Professor of Physiology and Biophysics at Weill Cornell Medical College. "With Ultima's new sequencing technology, we are able to turn these visions into reality, and with its commercial release, we are excited to be able to access the platform in the field to think bigger about how we deploy genomics on Earth (and in space) to accelerate our understanding of biology and advance precision medicine."

In addition to the product improvements made during Early Access, Ultima has also established partnerships with several leaders across the industry to improve the workflow and provide multiple sources for upstream library preparation reagents as well as streamline downstream analysis designed specifically for Ultima’s technology.

Ultima will be introducing the UG 100™ and will be providing additional information about its ppmSeq™ technology on February 6^th at the AGBT conference as part of its Gold Sponsorship plenary presentation.

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130828872/en/